# Study of AVZO-021 in Patients With Advanced Solid Tumors

> **NCT05867251** · PHASE1,PHASE2 · RECRUITING · sponsor: **Avenzo Therapeutics, Inc.** · enrollment: 430 (estimated)

## Conditions studied

- Advanced Solid Tumor
- HR+/HER2- Breast Cancer
- HR+, HER2-, Advanced Breast Cancer
- CCNE1 Amplification
- Epithelial Ovarian Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer
- Endometrial Cancer
- TNBC - Triple-Negative Breast Cancer

## Interventions

- **DRUG:** AVZO-021
- **DRUG:** Palbociclib
- **DRUG:** Fulvestrant
- **DRUG:** Letrozole
- **DRUG:** Ribociclib
- **DRUG:** Abemaciclib
- **DRUG:** Carboplatin
- **DRUG:** Sacituzumab Govitecan-hziy

## Key facts

- **NCT ID:** NCT05867251
- **Lead sponsor:** Avenzo Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-30
- **Primary completion:** 2028-01-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 430 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05867251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05867251, "Study of AVZO-021 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05867251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*